Online inquiry

IVTScrip™ mRNA-Anti-F, MEDI-8897(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11434MR)

This product GTTS-WQ11434MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets F gene. The antibody can be applied in Respiratory Syncytial Virus (RSV) infection research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
UniProt ID P03420
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-F, MEDI-8897(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ11434MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9789MR IVTScrip™ mRNA-Anti-PCSK9, JS002(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA JS002
GTTS-WQ6036MR IVTScrip™ mRNA-Anti-IL6, CNTO 136(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CNTO 136
GTTS-WQ8117MR IVTScrip™ mRNA-Anti-TNFRSF10B, HGS-ETR2(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA HGS-ETR2
GTTS-WQ15807MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, XmAb14045(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA XmAb14045
GTTS-WQ14263MR IVTScrip™ mRNA-Anti-ERBB3, RG-7116(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RG-7116
GTTS-WQ13972MR IVTScrip™ mRNA-Anti-GP, REGN3470-3471-3479(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA REGN3470-3471-3479
GTTS-WQ15608MR IVTScrip™ mRNA-Anti-SLC29A2, VAL-1221(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA VAL-1221
GTTS-WQ3678MR IVTScrip™ mRNA-Anti-F11, BAY 1213790(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BAY 1213790
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW